Proactive Investors - Run By Investors For Investors

Benchmark makes breakthrough discovery in combating infection in tilapia

"We believe that this breakthrough will allow the industry to expand production of this cost effective, high-quality, protein source to meet global demand for protein,” said chief executive Malcolm Pye.
Tilapia
Tilapia is the world's second most farmed fish

Benchmark Holdings PLC (LON:BMK) shares floated higher on Thursday following news it has made a breakthrough discovery in increasing genetic resistance to a common infection that affects tilapia fish.

The aquaculture and genetics firm has identified a quantitative trait locus, a small section of DNA, that is linked to higher levels of resistance to Streptococcus iniae, a bacteria that kills tilapia raised in fish farms.

The company has applied for a patent for the discovery.

READ: Benchmark shrugs off challenging shrimp market to deliver earnings growth

Tilapia is the world's second most farmed fish with 6.3 million tonnes of production in 2018 at an estimated value of £6.6bn, according to the United Nations Food and Agriculture Organisation. 

"We believe that this breakthrough will allow the industry to expand production of this cost effective, high-quality, protein source to meet global demand for protein,” said chief executive Malcolm Pye.

“We have seen first-hand how devastating Streptococcus is to the industry and with the introduction of this new technology we can drive improvements in sustainability and profitability for our customers."

In lunchtime trading, shares in Benchmark were 3% higher at 52p.

 -- Adds share price --

View full BMK profile View Profile

Benchmark Holdings PLC Timeline

Newswire
July 09 2019

Related Articles

picture of a knee
May 20 2019
We take a closer look at Collagen Solutions, which received third-party validation of its business model in the form of outside investment from a blue-chip US agriculture company
1537236236_main-better-use.jpg
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
Scientists in a lab
January 31 2019
CEO Gary Phillips says Pharmaxis’ healthy cash balance gives it time to choose between in-house and partnering options.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use